Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an...
Saved in:
Main Authors: | Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/5/e008025.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01) -
Post-translational modifications as a key mechanism for herpes simplex virus type I evasion of host innate immunity
by: Yongxing Zhang, et al.
Published: (2025-02-01) -
Assessment of Herpes Simplex Virus Type 1 and 2 by IHC in Association with CD14 Antigen in Placental Tissues from Women with Miscarriage
by: Zainab A. Hamid, et al.
Published: (2018-07-01) -
When herpes zoster is not herpes: A case of statin-induced myopathy complicated by drug allergies
by: Hira Khalid Kareem, et al.
Published: (2025-01-01) -
Koi Herpes Virus (KHV) Disease
by: Kathleen H. Hartman, et al.
Published: (2004-07-01)